VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2022 | MYLOX-1: Phase IIa study of GB2064, an oral LOXL-2 inhibitor in myelofibrosis

Claire Harrison, MD, DM, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, shares her excitement for the recently launched MYLOX-1 study (NCT04679870) which is looking at the impact of LOXL-2 inhibition in patients with myelofibrosis (MF). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Research funding: Celgene, Constellation, Novartis
Advisory role: AbbVie, AOP, BMS, Celgene, CTI, Novartis, Galacteo, Geron, Gilead, Janssen, Keros, Promedior, Roche, Shire, Sierra

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter